explore -WSS

explore

author：fashion 2025-10-02 10:45:33 - browse：25

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Cue Health, Covid

leisure time

WSS

The problem with charging patients to message their doctors

Digital health: a case of mistaken identity

ASCO eve: Let’s set the table for this year's meeting

Novo Nordisk obesity pill bests Wegovy in early trial

Amylyx ALS drug failure raises questions and concerns

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

focus

explore

explore

Bright Health sells Medicare Advantage business to Molina

Scrutiny of post

Wildfire smoke exposes gaps in outdoor worker protections

Change Healthcare payments predicted restored March 15

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biogen joins immunology wave with $1.15 billion acquisition of HI

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Study finds gene variants tied to breast cancer risk in Black women

Bright Health sells Medicare Advantage business to Molina

H5N1 bird flu outbreak: Second human case reported, in Michigan

hotspot

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

For longer

First medicine developed to treat MASH expected to be approved soon

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Change Healthcare cyberattack prompts Medicare loan program

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

leisure time

entertainment

knowledge

hotspot